ロード中...
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report
INTRODUCTION: We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment. MATERIAL AND METHODS: Patients with unresectable MM and no symptomatic effusions were given dasatinib 70 mg twice daily as part of a 28-d...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3308128/ https://ncbi.nlm.nih.gov/pubmed/22425926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318248242c |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|